The Latest
This Week in HIV Research: Solving the Riddle of Poor PrEP Uptake
July 30, 2020: HIV prevention shortfalls among adolescents of color; PrEP use among trans people; PrEP information gaps among women of color; the case for vacation-based (a.k.a. episodic) PrEP.
What Are the New HIV Treatment and Prevention Drugs Under Development in 2020?
Richard Jefferys of Treatment Action Group discusses the pipeline for new modalities being explored for treatment, PrEP, vaccine, and cure.
This Week in HIV Research: The Mind Matters
July 23, 2020: Depression and HIV risk mitigation among MSM; a consistent HIV provider is good for CD4 and viral load; spirituality and HIV prevention; HCV treatment access and reinfection risk.
This Week in HIV Research: Links in a Chain
July 16, 2020: Starting HIV treatment during hospitalization for people who use drugs; type of substance use affects viral suppression odds; benefits of a cross-disciplinary medical support team; does STI recency dictate PrEP necessity for women?
This Week in HIV Research: Do As We Say, Not As We Do
July 9, 2020: Abysmal HIV testing rates in U.S. ambulatory care settings; STI testing frequency in PrEP users; trends in U.S. PrEP uptake; integrating opioid therapy with HCV care in people who inject drugs.
Investigational PrEP Injection, Dosed Every Other Month, Beats Daily PrEP in Phase 3 Study
New data presented at AIDS 2020 show the long-acting injectable drug cabotegravir proved superior to daily oral TDF/FTC for MSM and transgender women.
Does Taking HIV Meds Reduce the Odds of COVID-19? Experts Say, ‘Not So Fast’
A newly published study linking HIV medication to reduction in COVID-19 risk has many problems, experts warn.
This Week in HIV Research: Existing Solutions Won't Close the Race Gap
June 18, 2020: Existing evidence-based interventions aren't enough to close HIV's racial gap; transgender patient outcomes in the HIV care continuum; meeting long-term needs of formerly incarcerated people; acute respiratory illness severity and HIV status.
New Study Shows Effectiveness of On-Demand PrEP
Kaiser Permanente’s 2-1-1 pre-exposure prophylaxis (PrEP) program shows event-driven dosing works.
This Week in HIV Research: Setting a New Bar
June 11, 2020: Diagnosis rates within a year of infection; rates of intentional non-daily PrEP use; neurological development in children of birth parents with HIV; point-of-care urine test to assess tenofovir levels.